5-Amino-1mq Human Trials
As an emerging selective small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), 5-Amino-1MQ has generated significant interest across metabolic research disciplines. This analysis evaluates the existing preclinical evidence, current clinical research landscape, cellular mechanisms of action, and analytical verification standards required for rigorous laboratory investigations.
Quick answer
As an emerging selective small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), 5-Amino-1MQ has generated significant interest across metabolic research disciplines. This analysis evaluates the existing preclinical evidence, current clinical research landscape, cellular mechanisms of action, and analytical verification standards required for rigorous laboratory investigations.
Key takeaways
- Currently, there are no published Phase I, II, or III human clinical trials evaluated or approved by regulatory authorities for [5-Amino-1MQ](/research-peptides/5-amino-1mq).
- [5-Amino-1MQ](/research-peptides/5-amino-1mq) (5-amino-1-methylquinolinium) functions as a membrane-permeable, selective small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT).
- Nicotinamide adenine dinucleotide ([NAD+](/research-peptides/nad-plus)) is a fundamental coenzyme governing mitochondrial electron transport, oxidative phosphorylation, and sirtuin-mediated epigenetic regulation.
- In rodent models of diet-induced obesity (DIO), researchers have observed that elevated NNMT activity strongly correlates with reduced basal metabolic rate and compromised mitochondrial efficiency in white adipose tissue (WAT).
Current Status of 5-Amino-1MQ Human Clinical Trials
Currently, there are no published Phase I, II, or III human clinical trials evaluated or approved by regulatory authorities for 5-Amino-1MQ. While the compound is widely cited in biochemical literature, available scientific data is derived exclusively from in vitro cell cultures and preclinical animal models. Researchers seeking verified reference materials for non-clinical studies can inspect high-purity lots of 5-Amino-1MQ engineered for laboratory applications.
The lack of formal human trial data necessitates that all experimental protocols involving 5-Amino-1MQ remain strictly confined to in vitro assays and preclinical animal research. Claims suggesting verified human efficacy, standardized human dosing schedules, or clinical therapeutic applications are unsupported by peer-reviewed human clinical trial literature. Investigators evaluating cellular energy pathways must rely on controlled in vitro and rodent models to characterize its pharmacological properties.
Molecular Mechanism: Nicotinamide N-Methyltransferase (NNMT) Inhibition
5-Amino-1MQ (5-amino-1-methylquinolinium) functions as a membrane-permeable, selective small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT). NNMT is a cytosolic enzyme predominantly expressed in adipose tissue, liver parenchyma, and structural cell lines, where it catalyzes the transfer of a methyl group from S-adenosylmethionine (SAM) to nicotinamide (NAM). This enzymatic reaction yields 1-methylnicotinamide (1-MNA) and S-adenosylhomocysteine (SAH).
By directly binding to and inhibiting NNMT activity, 5-Amino-1MQ limits the irreversible methylation of nicotinamide. Because 1-MNA cannot be readily recycled back into the NAD+ salvage pathway, elevated NNMT activity acts as a metabolic sink that depletes intracellular nicotinamide pools. Experimental inhibition of NNMT effectively preserves available nicotinamide substrates for salvage synthesis pathways, altering downstream cellular energetics. Researchers examining this enzymatic axis can explore comprehensive protocols within our research library.
Impact on Cellular NAD+ Salvage Pathways and Energetics
Nicotinamide adenine dinucleotide (NAD+) is a fundamental coenzyme governing mitochondrial electron transport, oxidative phosphorylation, and sirtuin-mediated epigenetic regulation. Preclinical studies suggest that reducing NNMT expression or pharmacologically blocking its active site with 5-Amino-1MQ prevents the degradation of nicotinamide, allowing rate-limiting enzymes such as nicotinamide phosphoribosyltransferase (NAMPT) to convert NAM into nicotinamide mononucleotide (NMN).
In vitro data indicate that preserving intracellular NAM via NNMT blockade leads to a measurable increase in intracellular NAD+ concentration. This elevation in NAD+ availability enhances sirtuin 1 (SIRT1) catalytic activity and promotes downstream expression of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α). The cascade supports mitochondrial biogenesis and enhances oxidative metabolism in cultured cell models. For broader context on NAD+ flux mechanisms, review our NAD+ pathway research guide.
Preclinical Findings: Adipocyte Metabolism and Mitochondrial Output
In rodent models of diet-induced obesity (DIO), researchers have observed that elevated NNMT activity strongly correlates with reduced basal metabolic rate and compromised mitochondrial efficiency in white adipose tissue (WAT). Pharmacological intervention with 5-Amino-1MQ in these animal models demonstrated marked alterations in systemic lipid utilization without changing baseline dietary intake.
Preclinical trial data show that treatment of high-fat diet-fed mice with 5-Amino-1MQ resulted in significant reductions in adipocyte volume, decreased weight gain, and improved systemic insulin sensitivity. Cellular analyses of isolated adipocytes revealed elevated basal oxygen consumption rates (OCR) and upregulation of thermogenic markers, suggesting that NNMT inhibition shifts adipocyte physiology toward higher energy expenditure. These preclinical findings underscore the compound's utility as a tool for studying lipid oxidation and metabolic rate regulation.
Comparative Analysis of Metabolic and Mitochondrial Research Compounds
When evaluating small molecules and peptides designed to modulate cellular energetics, investigators frequently compare 5-Amino-1MQ with alternative research compounds targeting parallel metabolic cascades. While 5-Amino-1MQ specifically targets cytosolic NNMT to conserve NAD+ precursor pools, compounds such as MOTS-c operate as mitochondrial-derived peptides that regulate nuclear gene expression during metabolic stress.
Similarly, research involving the synthetic estrogen-related receptor alpha (ERRα) agonist SLU-PP-332 focuses on directly stimulating oxidative muscle fiber transformation and mitochondrial respiration independently of NNMT pathways. While AICAR activates AMP-activated protein kinase (AMPK) to simulate low-energy cellular states, 5-Amino-1MQ acts upstream by modulating precursor availability for NAD+ synthesis. Utilizing combinations of these distinct molecules allows laboratory researchers to isolate specific rate-limiting steps within cellular energy networks. Additional compounds for comparative assay design are available across our full research compounds catalog.
In Vitro Assay Design and Preclinical Experimental Methodologies
Designing robust in vitro protocols with 5-Amino-1MQ requires careful consideration of cell-type expression profiles, baseline NNMT activity, and assay duration. Primary adipocytes, 3T3-L1 differentiated cell lines, and primary hepatocytes represent common cellular models due to their high baseline expression of NNMT. Initial range-finding studies typically utilize concentrations between 1 µM and 50 µM to establish half-maximal inhibitory concentrations ($IC_{50}$) for target NNMT inhibition.
Investigators monitor enzymatic inhibition by measuring cellular concentrations of 1-MNA, SAM, and SAH via liquid chromatography-mass spectrometry (LC-MS). Secondary endpoint assays frequently measure intracellular NAD+/NADH ratios, fluorometric ATP production, and real-time oxygen consumption using extracellular flux analyzers. Control experiments should incorporate vehicle-only controls to distinguish specific NNMT inhibition from non-specific cellular responses.
Reconstitution, Solubility, and Laboratory Storage Protocols
5-Amino-1MQ is supplied as a highly purified solid mass requiring proper reconstitution prior to experimental deployment. The compound exhibits optimal solubility in organic solvents such as dimethyl sulfoxide (DMSO) and dimethylformamide (DMF), achieving stock solution concentrations up to 20 mg/mL. Aqueous solubility in standard phosphate-buffered saline (PBS, pH 7.2) is limited; therefore, initial dissolution in DMSO followed by step-down dilution into working culture media is strongly recommended.
Lyophilized powders should be stored at -20°C in a desiccated environment protected from direct light exposure. Following reconstitution in DMSO, stock solutions should be aliquoted into single-use microcentrifuge tubes to prevent repeated freeze-thaw cycles and stored at -80°C. Working solutions prepared in aqueous buffer should be utilized immediately within the same experimental block to ensure molecular integrity and consistent potency.
Quality Verification: Analytical Standards and COA Requirements
Reproducibility in preclinical research demands rigorous analytical verification of small molecules and peptides. PX1 Research subjects every lot of 5-Amino-1MQ to stringent third-party testing protocols in ISO 17025 accredited analytical laboratories located within the USA. Each lot is supplied with a comprehensive Certificate of Analysis (COA) documenting identity, purity, and residual impurity profiles.
Analytical verification includes high-performance liquid chromatography (HPLC) to confirm chemical purity exceeding 98.0%, alongside electrospray ionization mass spectrometry (ESI-MS) to confirm exact molecular weight and chemical structure. Furthermore, samples undergo bacterial endotoxin testing via Limulus Amebocyte Lysate (LAL) assays to ensure suitability for sensitive cell culture and animal tissue preparations. Institutional laboratories requiring specialized sourcing or bulk material verification can review protocols through our wholesale research portal.
Frequently Asked Questions
Are there any published human clinical trials for 5-Amino-1MQ?
No. There are currently no published Phase I, II, or III human clinical trials for 5-Amino-1MQ. All published scientific literature relies exclusively on in vitro cell cultures and preclinical animal models.
What is the primary cellular mechanism of 5-Amino-1MQ?
5-Amino-1MQ acts as a selective inhibitor of nicotinamide N-methyltransferase (NNMT). By preventing the methylation of nicotinamide into 1-methylnicotinamide, it preserves nicotinamide pools for NAD+ synthesis.
How does NNMT inhibition alter intracellular NAD+ levels?
NNMT converts nicotinamide into 1-MNA, which cannot be recycled into NAD+. Inhibiting NNMT prevents this destruction of nicotinamide, leaving more substrate available for the salvage pathway to produce NAD+.
What solvent is recommended for reconstituting 5-Amino-1MQ for cell culture?
5-Amino-1MQ is most soluble in organic solvents such as DMSO. Researchers typically prepare concentrated stock solutions in DMSO before diluting into aqueous cell culture media for experimental treatments.
What purity levels are required for 5-Amino-1MQ in research assays?
Preclinical and in vitro assays require a purity level of at least 98.0%, verified by HPLC and ESI-MS, to ensure that observed metabolic effects are directly attributable to NNMT inhibition rather than synthetic impurities.
How should 5-Amino-1MQ stock solutions be stored long-term?
Lyophilized powder should be stored at -20°C in a desiccated container. Once reconstituted in DMSO, aliquots should be stored at -80°C to maintain stability and prevent degradation over multiple freeze-thaw cycles.
How does 5-Amino-1MQ differ from mitochondrial peptides like MOTS-c?
5-Amino-1MQ is a synthetic small molecule targeting the cytosolic enzyme NNMT to preserve NAD+ precursors, whereas MOTS-c is a mitochondria-derived peptide that directly regulates nuclear gene expression involved in metabolic homeostasis.
Does PX1 Research provide endotoxin data for 5-Amino-1MQ lots?
Yes. PX1 Research subjects all lots to third-party LAL testing to quantify bacterial endotoxin levels, ensuring suitability for delicate in vitro and animal research protocols.
Related pages
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.